Table of Contents
Chapter 1 Methodology And Scope
1.1 Market Segmentation And Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline:
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 List Of Secondary Sources
1.8 List Of Abbreviations
1.9 Objectives
1.9.1 Objective 1
1.9.2 Objective 2
1.9.3 Objective 3
1.9.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Market Definitions
3.3 Key Opportunities Prioritized
3.4 Market Dynamic Analysis
3.4.1 Rising Adoption Of Radiotherapy
3.4.2 Technological Advancements In Radiotherapy
3.4.3 Rising Prevalence Of Cancer
3.4.4 Increase In Healthcare Expenditure
3.4.5 Increasing APPLICATION OF Radiopharmaceuticals
3.5 Market Restraint Analysis
3.5.1 Lack Of Skilled Radiotherapy Professionals
3.5.2 Inadequate Radiation Infrastructure
3.5.3 Adverse Effects Of Radiotherapy
3.6 Business Environment Analysis
3.6.1 SWOT Analysis; By Factor (POLITICAL & LEGAL, Economic And Technological)
3.6.2 Porter’s Five Forces Analysis
Chapter 4 Radiation Oncology Market – Segment Analysis, By Type, 2018 – 2030 (USD Million)
4.1 Radiation Oncology Market: Type Movement Analysis
4.2 External Beam Radiation Therapy
4.2.1 External Beam Radiation Therapy Market, 2018 – 2030 (USD Million)
4.2.2 Electron-Emitting High Energy Linear Accelerators
4.2.2.1 Electron-Emitting High Energy Linear Accelerators Market, 2018 – 2030 (USD Million)
4.2.3 Compact Advanced Radiotherapy Systems
4.2.3.1 Compact Advanced Radiotherapy Systems Market, 2018 – 2030 (USD Million)
4.2.3.2 Cyberknife
4.2.3.2.1 Cyberknife Market, 2018 – 2030 (USD Million)
4.2.3.3 Gamma Knife
4.2.3.3.1 Gamma Knife Market, 2018 – 2030 (USD Million)
4.2.3.4 Tomotherapy
4.2.3.4.1 Tomotherapy Compact Market, 2018 – 2030 (USD Million)
4.2.4 Proton Therapy
4.2.4.1 Proton Therapy Market, 2018 – 2030 (USD Million)
4.2.4.2 Cyclotron
4.2.4.2.1 Cyclotron Market, 2018 – 2030 (USD Million)
4.2.4.3 Synchrotron
4.2.4.3.1 Synchrotron Market, 2018 – 2030 (USD Million)
4.3 Internal Beam Radiation Therapy
4.3.1 Internal Beam Radiation Therapy Market, 2018 – 2030 (USD Million)
4.3.2 Brachytherapy
4.3.2.1 Brachytherapy Market, 2018 – 2030 (USD Million)
4.3.2.2 Seeds
4.3.2.2.1 Seeds Market, 2018 – 2030 (USD Million)
4.3.2.3 Applicators And After-Loaders
4.3.2.3.1 Applicators And After-Loaders Market, 2018 – 2030 (USD Million)
4.3.2.4 Electronic Brachytherapy
4.3.2.4.1 Electronic Brachytherapy Market, 2018 – 2030 (USD Million)
4.3.3 Systemic Beam Radiation Therapy
4.3.3.1 Systemic Beam Radiation Therapy Market, 2018 – 2030 (USD Million)
4.3.4 Others
4.3.4.1 Others Market, 2016-2028 (USD Million)
Chapter 5 Radiation Oncology Market – Segment Analysis, By Technology, 2018 – 2030 (USD Million)
5.1 Radiation Oncology Market: Technology Movement Analysis
5.2 External Beam Radiation Therapy (EBRT)
5.2.1 EBRT Market, 2018 – 2030 (USD Million)
5.2.2 Image-Guided Radiation Therapy (IGRT)
5.2.2.1 IGRT Market, 2018 – 2030 (USD Million)
5.2.3 Intensity Modulated Radiotherapy (IMRT)
5.2.3.1 IMRT Market, 2018 – 2030 (USD Million)
5.2.4 Stereotactic Radiotherapy
5.2.4.1 Stereotactic Radiotherapy Market, 2018 – 2030 (USD Million)
5.2.5 Proton Beam Therapy
5.2.5.1 Proton Beam Therapy Market, 2018 – 2030 (USD Million)
5.2.6 3D Conformal Radiotherapy (3D-CRT)
5.2.6.1 3D-CRT Market, 2018 – 2030 (USD Million)
5.2.7 Volumetric Modulated Arc Therapy (VMAT)
5.2.7.1 VMAT Market, 2018 – 2030 (USD Million)
5.3 Brachytherapy
5.3.1 Brachytherapy Market, 2018 – 2030 (USD Million)
5.3.2 Low Dose Rate (LDR) Brachytherapy
5.3.2.1 LDR Brachytherapy Market, 2018 – 2030 (USD Million)
5.3.3 High Dose Rate (HDR) Brachytherapy
5.3.3.1 HDR Brachytherapy Market, 2018 – 2030 (USD Million)
Chapter 6 Radiation Oncology Market – Segment Analysis, By Application, 2018 – 2030 (USD Million)
6.1 Radiation Oncology Market: Application Movement Analysis
6.2 External Beam Radiation Therapy (EBRT)
6.2.1 Prostate Cancer
6.2.1.1 Prostate Cancer Market, 2018 – 2030 (USD Million)
6.2.2 Breast Cancer
6.2.2.1 Breast Cancer Market, 2018 – 2030 (USD Million)
6.2.3 Lung Cancer
6.2.3.1 Lung Cancer Market, 2018 – 2030 (USD Million)
6.2.4 Head And Neck Cancer
6.2.4.1 Head And Neck Cancer Market, 2018 – 2030 (USD Million)
6.2.5 Colorectal Cancer
6.2.5.1 Colorectal Cancer Market, 2018 – 2030 (USD Million)
6.2.6 Others
6.2.6.1 Others Market, 2018 – 2030 (USD Million)
6.3 Internal Beam Radiation Therapy
6.3.1 Prostate Cancer
6.3.1.1 Prostate Cancer Market, 2018 – 2030 (USD Million)
6.3.2 Gynecologic Cancer
6.3.2.1 Gynecologic Cancer Market, 2018 – 2030 (USD Million)
6.3.3 Breast Cancer
6.3.3.1 Breast Cancer Market, 2018 – 2030 (USD Million)
6.3.4 Cervical Cancer
6.3.4.1 Cervical Cancer Market, 2018 – 2030 (USD Million)
6.3.5 Penile Cancer
6.3.5.1 Penile Cancer Market, 2018 – 2030 (USD Million)
6.3.6 Others
6.3.6.1 Others Market, 2018 – 2030 (USD Million)
Chapter 7 Radiation Oncology Market – Segment Analysis, By Region, 2018 – 2030 (USD Million)
7.1 Definition & Scope
7.2 North America
7.2.1 North America, SWOT Analysis
7.2.2 U.S.
7.2.2.1 U.S. Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.2.2 Key Country Dynamics
7.2.2.3 Target Disease Prevalence
7.2.2.4 Competitive Scenario
7.2.2.5 Regulatory Framework
7.2.2.6 Reimbursement Scenario
7.2.3 Canada
7.2.3.1 Canada Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.2.3.2 Key Country Dynamics
7.2.3.3 Target Disease Prevalence
7.2.3.4 Competitive Scenario
7.2.3.5 Regulatory Framework
7.2.3.6 Reimbursement Scenario
7.3 Europe
7.3.1 Europe, SWOT Analysis
7.3.2 U.K.
7.3.2.1 U.K. Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.2.2 Key Country Dynamics
7.3.2.3 Target Disease Prevalence
7.3.2.4 Competitive Scenario
7.3.2.5 Regulatory Framework
7.3.2.6 Reimbursement Scenario
7.3.3 Germany
7.3.3.1 Germany Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.3.2 Key Country Dynamics
7.3.3.3 Target Disease Prevalence
7.3.3.4 Competitive Scenario
7.3.3.5 Regulatory Framework
7.3.3.6 Reimbursement Scenario
7.3.4 France
7.3.4.1 France Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.4.2 Key Country Dynamics
7.3.4.3 Target Disease Prevalence
7.3.4.4 Competitive Scenario
7.3.4.5 Regulatory Framework
7.3.4.6 Reimbursement Scenario
7.3.5 Italy
7.3.5.1 Italy Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.5.2 Key Country Dynamics
7.3.5.3 Target Disease Prevalence
7.3.5.4 Competitive Scenario
7.3.5.5 Regulatory Framework
7.3.5.6 Reimbursement Scenario
7.3.6 Spain
7.3.6.1 Spain Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.6.2 Key Country Dynamics
7.3.6.3 Target Disease Prevalence
7.3.6.4 Competitive Scenario
7.3.6.5 Regulatory Framework
7.3.6.6 Reimbursement Scenario
7.3.7 Sweden
7.3.7.1 Sweden Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.7.2 Key Country Dynamics
7.3.7.3 Target Disease Prevalence
7.3.7.4 Competitive Scenario
7.3.7.5 Regulatory Framework
7.3.7.6 Reimbursement Scenario
7.3.8 Denmark
7.3.8.1 Denmark Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.8.2 Key Country Dynamics
7.3.8.3 Target Disease Prevalence
7.3.8.4 Competitive Scenario
7.3.8.5 Regulatory Framework
7.3.8.6 Reimbursement Scenario
7.3.9 Norway
7.3.9.1 Norway Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.3.9.2 Key Country Dynamics
7.3.9.3 Target Disease Prevalence
7.3.9.4 Competitive Scenario
7.3.9.5 Regulatory Framework
7.3.9.6 Reimbursement Scenario
7.3.10 Rest Of Europe
7.3.10.1 Rest Of Europe Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific, SWOT Analysis
7.4.2 India
7.4.2.1 India Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4.2.2 Key Country Dynamics
7.4.2.3 Target Disease Prevalence
7.4.2.4 Competitive Scenario
7.4.2.5 Regulatory Framework
7.4.2.6 Reimbursement Scenario
7.4.3 China
7.4.3.1 China Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4.3.2 Key Country Dynamics
7.4.3.3 Target Disease Prevalence
7.4.3.4 Competitive Scenario
7.4.3.5 Regulatory Framework
7.4.3.6 Reimbursement Scenario
7.4.4 Japan
7.4.4.1 Japan Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4.4.2 Key Country Dynamics
7.4.4.3 Target Disease Prevalence
7.4.4.4 Competitive Scenario
7.4.4.5 Regulatory Framework
7.4.4.6 Reimbursement Scenario
7.4.5 Australia
7.4.5.1 Australia Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4.5.2 Key Country Dynamics
7.4.5.3 Target Disease Prevalence
7.4.5.4 Competitive Scenario
7.4.5.5 Regulatory Framework
7.4.5.6 Reimbursement Scenario
7.4.6 South Korea
7.4.6.1 South Korea Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4.6.2 Key Country Dynamics
7.4.6.3 Target Disease Prevalence
7.4.6.4 Competitive Scenario
7.4.6.5 Regulatory Framework
7.4.6.6 Reimbursement Scenario
7.4.7 THAILAND
7.4.7.1 Thailand Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.4.7.2 Key Country Dynamics
7.4.7.3 Target Disease Prevalence
7.4.7.4 Competitive Scenario
7.4.7.5 Regulatory Framework
7.4.7.6 Reimbursement Scenario
7.4.8 Rest Of APAC
7.4.8.1 Rest Of APAC Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America, SWOT Analysis
7.5.2 Mexico
7.5.2.1 Mexico Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5.2.2 Key Country Dynamics
7.5.2.3 Target Disease Prevalence
7.5.2.4 Competitive Scenario
7.5.2.5 Regulatory Framework
7.5.2.6 Reimbursement Scenario
7.5.3 Brazil
7.5.3.1 Brazil Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5.3.2 Key Country Dynamics
7.5.3.3 Target Disease Prevalence
7.5.3.4 Competitive Scenario
7.5.3.5 Regulatory Framework
7.5.3.6 Reimbursement Scenario
7.5.4 Argentina
7.5.4.1 Argentina Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.5.4.2 Key Country Dynamics
7.5.4.3 Target Disease Prevalence
7.5.4.4 Competitive Scenario
7.5.4.5 Regulatory Framework
7.5.4.6 Reimbursement Scenario
7.5.5 Rest Of LATAM
7.5.5.1 Rest Of LATAM Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6 MEA
7.6.1 Middle East & Africa, SWOT Analysis
7.6.2 South Africa
7.6.2.1 South Africa Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.2.2 Key Country Dynamics
7.6.2.3 Target Disease Prevalence
7.6.2.4 Competitive Scenario
7.6.2.5 Regulatory Framework
7.6.2.6 Reimbursement Scenario
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.3.2 Key Country Dynamics
7.6.3.3 Target Disease Prevalence
7.6.3.4 Competitive Scenario
7.6.3.5 Regulatory Framework
7.6.3.6 Reimbursement Scenario
7.6.4 UAE
7.6.4.1 UAE Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.4.2 Key Country Dynamics
7.6.4.3 Target Disease Prevalence
7.6.4.4 Competitive Scenario
7.6.4.5 Regulatory Framework
7.6.4.6 Reimbursement Scenario
7.6.5 Kuwait
7.6.5.1 Kuwait Market Estimates And Forecast, 2018 – 2030 (USD Million)
7.6.5.2 Key Country Dynamics
7.6.5.3 Target Disease Prevalence
7.6.5.4 Competitive Scenario
7.6.5.5 Regulatory Framework
7.6.5.6 Reimbursement Scenario
7.6.6 Rest Of MEA
7.6.6.1 Rest Of MEA Market Estimates And Forecast, 2018 – 2030 (USD Million)
Chapter 8 Competitive Landscape
8.1 Public Companies
8.1.1 Company Market Position Analysis
8.1.2 Competitive Dashboard Analysis
8.1.3 Strategic Framework
8.2 Private Companies
8.2.1 List Of Key Emerging Companies/Technology Disruptors/Innovators
8.2.2 Regional Network Map
8.3 Company Profiles
8.3.1 Varian Medical Systems, Inc. (A Part Of Siemens Healthineers)
8.3.1.1 Company Overview
8.3.1.2 Financial Performance
8.3.1.3 Product Benchmarking
8.3.1.4 Strategic Initiatives
8.3.2 Elekta AB
8.3.2.1 Company Overview
8.3.2.2 Financial Performance
8.3.2.3 Product Benchmarking
8.3.2.4 Strategic Initiatives
8.3.3 Accuray Incorporated
8.3.3.1 Company Overview
8.3.3.2 Financial Performance
8.3.3.3 Product Benchmarking
8.3.3.4 Strategic Initiatives
8.3.4 Ion Beam Applications (IBA).
8.3.4.1 Company Overview
8.3.4.2 Financial Performance
8.3.4.3 Product Benchmarking
8.3.4.4 Strategic Initiatives
8.3.5 BD (Becton, Dickinson And Company)
8.3.5.1 Company Overview
8.3.5.2 Financial Performance
8.3.5.3 Product Benchmarking
8.3.5.4 Strategic Initiatives
8.3.6 Isoray Medical
8.3.6.1 Company Overview
8.3.6.2 Financial Performance
8.3.6.3 Product Benchmarking
8.3.6.4 Strategic Initiatives
8.3.7 Mevion Medical Systems
8.3.7.1 Company Overview
8.3.7.2 Product Benchmarking
8.3.7.3 Strategic Initiatives
8.3.8 Nordion Inc.
8.3.8.1 Company Overview
8.3.8.2 Product Benchmarking
8.3.8.3 Strategic Initiatives
8.3.9 NTP Radioisotopes SOC Ltd.
8.3.9.1 Company Overview
8.3.9.2 Financial Performance
8.3.9.3 Product Benchmarking
8.3.9.4 Strategic Initiatives
8.3.10 Curium
8.3.10.1 Company Overview
8.3.10.2 Product Benchmarking
8.3.10.3 Strategic Initiatives
8.3.11 VIEWRAY TECHNOLOGIES, INC.
8.3.11.1 Company Overview
8.3.11.2 Financial Performance
8.3.11.3 Product Benchmarking
8.3.11.4 Strategic Initiatives